The evolution of the locoregional therapy of breast cancer

Oncologist

Volumn 16, Issue 10, 2011, Pages 1367-1379

  Ho, Alice ^a   Morrow, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast surgery; Lumpectomy; Partial breast irradiation; Sentinel node

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PLACEBO; TAMOXIFEN CITRATE; TRASTUZUMAB;

ARTICLE; AXILLARY LYMPH NODE; BRACHYTHERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DRUG EFFICACY; ELECTRON THERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTRAOPERATIVE RADIOTHERAPY; LOCOREGIONAL THERAPY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PATIENT SAFETY; PHOTON THERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; THERAPY EFFECT; TREATMENT OUTCOME;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY;

EID: 80054822643     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0223     Document Type: Article

References (88)

1. Adair F, Berg J, Joubert L et al. Long-term followup of breast cancer patients: The 30-year report. Cancer 1974;33:1145-1150.
2. Fisher B. Sounding board. Breast-cancer management: Alternatives to radical mastectomy. N Engl J Med 1979;301:326 -328.
3. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-2106.
4. Fisher B, Jeong JH, Anderson S et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567- 575.
5. Fisher B, Redmond C, Fisher ER et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-681.
6. Arriagada R, Lê MG, Rochard F et al. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996;14: 1558-1564.
7. Blichert-Toft M, Rose C, Andersen JA et al. Danish randomized trial comparing breast conservation therapy with mastectomy: Six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr 1992;(11):19 -25.
8. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233-1241.
9. Poggi MM, Danforth DN, Sciuto LC et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: The National Cancer Institute randomized trial. Cancer 2003;98: 697-702.
10. van Dongen JA, Voogd AC, Fentiman IS et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143-1150.
11. Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-1232.
12. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529 -1542.
13. Fisher B, Dignam J, Mamounas EP et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996;14:1982-1992.
14. Anderson SJ, Wapnir I, Dignam JJ et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breastconserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 2009;27: 2466-2473.
15. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684.
16. Mamounas EP, Tang G, Fisher B et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677-1683.
17. Millar EK, Graham PH, O'Toole SA et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009;27: 4701-4708.
18. Nguyen PL, Taghian AG, Katz MS et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373-2378.
19. Kyndi M, Sørensen FB, Knudsen H et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 2008;26:1419-1426.
20. Houssami N, Macaskill P, Marinovich ML et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer 2010;46:3219-3232.
21. Holland R, Veling SH, Mravunac M et al. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 1985;56:979-990.
22. Houssami N, Ciatto S, Macaskill P et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: Systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:3248-3258.
23. Hwang N, Schiller DE, Crystal P et al. Magnetic resonance imaging in the planning of initial lumpectomy for invasive breast carcinoma: Its effect on ipsilateral breast tumor recurrence after breast-conservation therapy. Ann Surg Oncol 2009;16:3000-3009.
24. Solin LJ, Orel SG, Hwang WT et al. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386-391.
25. Bleicher RJ, Ciocca RM, Egleston BL et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009;209:180-187; quiz 294-295.
26. Katipamula R, Degnim AC, Hoskin T et al. Trends in mastectomy rates at the Mayo Clinic Rochester: Effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009;27:4082-4088.
27. Morrow M, Jagsi R, Alderman AK et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 2009;302: 1551-1556.
28. Morrow M, Harris JR. Practice guideline for the breast conservation therapy in the management of invasive breast cancer. J Am Coll Surg 2007; 205:362-376.
29. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007;94:1189-1200.
30. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
31. van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-4237.
32. Chen JH, Feig B, Agrawal G et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008;112:17-26.
33. Julius T, Kemp SE, Kneeshaw PJ et al. MRI and conservative treatment of locally advanced breast cancer. Eur J Surg Oncol 2005;31:1129-1134.
34. Bartelink H, Horiot JC, Poortmans PM et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259-3265.
35. Katz SJ, Lantz PM, Janz NK et al. Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol 2005;23:5526-5533.
36. Fletcher GH. Hypofractionation: Lessons from complications. Radiother Oncol 1991;20:10-15.
37. START Trialists' Group; Bentzen SM, Agrawal RK, Aird EG et al. TheUK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 2008;9:331-341.
38. START Trialists' Group; Bentzen SM, Agrawal RK, Aird EG et al. TheUK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet 2008;371:1098-1107.
39. Whelan TJ, Pignol JP, LevineMNet al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513-520.
40. Haviland JS, Yarnold JR, Bentzen SM. Hypofractionated radiotherapy for breast cancer. N Engl J Med 2010;362:1843; author reply 1843-1844.
41. Smith BD, Bentzen SM, Correa CR et al. Fractionation for whole breast irradiation: An American Society for Radiation Oncology (ASTRO) evidence- based guideline. Int J Radiat Oncol Biol Phys 2011;81:59-68.
42. Yarnold J, Bloomeld D, LeVay J. Prospective randomized trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in women with early breast cancer (FAST) trial. Clin Oncol 2004;16:S30.
43. Alonso-Basanta M, Ko J, Babcock M et al. Coverage of axillary lymph nodes in supine vs. prone breast radiotherapy. Int J Radiat Oncol Biol Phys 2009;73:745-751.
44. Kirby AM, Evans PM, Donovan EM et al. Prone versus supine positioning for whole and partial-breast radiotherapy: A comparison of non-target tissue dosimetry. Radiother Oncol 2010;96:178-184.
45. Stegman LD, Beal KP, Hunt MA et al. Long-term clinical outcomes of whole-breast irradiation delivered in the prone position. Int J Radiat Oncol Biol Phys 2007;68:73-81.
46. Liljegren G, Holmberg L, Bergh J et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: A randomized trial. J Clin Oncol 1999;17:2326-2333.
47. Veronesi U, Marubini E, Mariani L et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: Long-term results of a randomized trial. Ann Oncol 2001;12:997-1003.
48. MammoSite®. Hologic. Available at http://www.mammosite.com/physicians/, accessed June 3, 2011.
49. Vicini F, Beitsch P, Quiet C et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2011;79:808-817.
50. Arthur DW, Winter K, Kuske RR et al. A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: Tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys 2008;72:467-473.
51. Chao KK, Vicini FA, WallaceMet al. Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: The William Beaumont Hospital experience. Int J Radiat Oncol Biol Phys 2007;69:32-40.
52. Patel RR, Christensen ME, Hodge CW et al. Clinical outcome analysis in "high-risk" versus "low-risk" patients eligible for National Surgical Adjuvant Breast and Bowel B-39/Radiation Therapy Oncology Group 0413 trial: Five-year results. Int J Radiat Oncol Biol Phys 2008;70:970-973.
53. Vicini FA, Antonucci JV, Wallace M et-aletal/et-al. Long-term efficacy and patterns of failure after accelerated partial breast irradiation: A molecular assaybased clonality evaluation. Int J Radiat Oncol Biol Phys 2007;68:341-346.
54. Dodwell DJ, Dyker K, Brown J et al. A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clin Oncol (R Coll Radiol) 2005;17:618-622.
55. Ribeiro GG, Dunn G, Swindell R et al. Conservation of the breast using two different radiotherapy techniques: Interim report of a clinical trial. Clin Oncol (R Coll Radiol) 1990;2:27-34.
56. Ribeiro GG, Magee B, Swindell R et al. The Christie Hospital breast conservation trial: An update at 8 years from inception. Clin Oncol (R Coll Radiol) 1993;5:278-283.
57. Vaidya JS, Joseph DJ, Tobias JS et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): An international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010;376:91-102.
58. Yi M, Kronowitz SJ, Meric-Bernstam F et al. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer 2011;117:916-924.
59. Lanitis S, Tekkis PP, Sgourakis G et al. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: A metaanalysis of observational studies. Ann Surg 2010;251:632-639.
60. Lagios MD, Gates EA, Westdahl PR et al. A guide to the frequency of nipple involvement in breast cancer. A study of 149 consecutive mastectomies using a serial subgross and correlated radiographic technique. Am J Surg 1979;138:135-142.
61. Laronga C, Kemp B, JohnstonDet al. The incidence of occult nipple-areola complex involvement in breast cancer patients receiving a skin-sparing mastectomy. Ann Surg Oncol 1999;6:609-613.
62. Brachtel EF, Rusby JE, Michaelson JS et al. Occult nipple involvement in breast cancer: Clinicopathologic findings in 316 consecutive mastectomy specimens. J Clin Oncol 2009;27:4948-4954.
63. Rusby JE, Smith BL, Gui GP. Nipple-sparing mastectomy. Br J Surg 2010; 97:305-316.
64. Boneti C, Yuen J, Santiago C et al. Oncologic safety of nipple skin-sparing or total skin-sparing mastectomies with immediate reconstruction. J Am Coll Surg 2011;212:686-693; discussion 693-695.
65. Garwood ER, Moore D, Ewing C et al. Total skin-sparing mastectomy: Complications and local recurrence rates in 2 cohorts of patients. Ann Surg 2009;249:26-32.
66. Gerber B, Krause A, Dieterich M et al. The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: An extended follow-up study. Ann Surg 2009;249: 461-468.
67. Petit JY, Veronesi U, Orecchia R et al. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: One thousand and one cases of a five years experience at the European Institute of Oncology of Milan (EIO). Breast Cancer Res Treat 2009;117:333-338.
68. Benediktsson KP, Perbeck L, Geigant E et al. Touch sensibility in the breast after subcutaneous mastectomy and immediate reconstruction with a prosthesis. Br J Plast Surg 1997;50:443-449.
69. Giuliano AE, Dale PS, Turner RR et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-399; discussion 399-401.
70. Krag DN, Anderson SJ, Julian TB et al. Technical outcomes of sentinellymph- node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: Results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8:881-888.
71. Posther KE, McCall LM, Blumencranz PW et al. Sentinel node skills verification and surgeon performance: Data from a multicenter clinical trial for early-stage breast cancer. Ann Surg 2005;242:593-599; discussion 599-602.
72. Mansel RE, Fallowfield L, Kissin M et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst 2006;98:599-609.
73. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel- node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-553.
74. Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-933.
75. Veronesi U, Viale G, Paganelli G et al. Sentinel lymph node biopsy in breast cancer: Ten-year results of a randomized controlled study. Ann Surg 2010;251:595-600.
76. Grube BJ, Giuliano AE. Sentinel lymph node dissection. In: Harris JR, Lippman ME, Morrow M, et al., eds. Diseases of the Breast, Fourth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2010:542-561.
77. Gentilini O, Cremonesi M, Trifirò G et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 2004;15:1348-1351.
78. Pandit-Taskar N, Dauer LT, Montgomery L et al. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med 2006;47:1202-1208.
79. Hidar S, Bibi M, Gharbi O et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg 2009;7:272-275.
80. Stearns V, Ewing CA, Slack R et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002;9:235-242.
81. Lucci A, McCall LM, Beitsch PD et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007;25:3657-3663.
82. Giuliano AE, Hunt KK, BallmanKVet al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011;305:569-575.
83. Giuliano AE, McCall L, Beitsch P et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426-432; discussion 432-433.
84. Martelli G, Miceli R, Daidone MG et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: Results after 15 years of follow-up. Ann Surg Oncol 2011;18: 125-133.
85. International Breast Cancer Study Group; Rudenstam CM, Zahrieh D, Forbes JF et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol 2006;24: 337-344.
86. Veronesi U, Orecchia R, Zurrida S et al. Avoiding axillary dissection in breast cancer surgery: A randomized trial to assess the role of axillary radiotherapy. Ann Oncol 2005;16:383-388.
87. Greco M, Agresti R, Cascinelli N et al. Breast cancer patients treated without axillary surgery: Clinical implications and biologic analysis. Ann Surg 2000;232:1-7.
88. Grills IS, Kestin LL, Goldstein N et al. Risk factors for regional nodal failure after breast-conserving therapy: Regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes. Int J Radiat Oncol Biol Phys 2003;56:658-670.